| High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. | |
| | |
MedLine Citation:
|
PMID: 20504223 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: DNA excision repair gene expression plays a pivotal role in the resistance of platinum-based doublet chemotherapy of nonsmall cell lung cancer (NSCLC) in clinical practice. The aim of this study was to investigate the relationship of the excision repair cross-complementation group 1 (ERCC1) mRNA level in fresh tumor tissue and the efficacy of platinum-based chemotherapy of NSCLC. PATIENTS AND METHODS: 100 patients diagnosed with NSCLC, including stage IIIB with malignant pleural effusion, stage IV, and recurrent disease, were enrolled in this study. Before clinical treatment, tumor biopsy specimens were collected, and total RNA was purified to analyze ERCC1 mRNA level by real-time polymerase chain reaction assay. All patients were treated with platinum-based third-generation doublet chemotherapy. RESULTS: Patient median age was 60 years. Forty-seven patients had NSCLC with low expression of ERCC1 mRNA, and 53 patients had high expression of ERCC1 mRNA. Although the ERCC1 mRNA level was not correlated with the response rate (p = .665) and progression-free survival (median, 6.4 months vs. 5.5 months; p = .446), the high level of ERCC1 mRNA demonstrated a significant association with poor overall survival (median, 11 months vs. 17 months; p = .02). High level of ERCC1 mRNA was an independent prognostic factor for poor overall survival (p < .001) along with lack of disease control (p < .001). CONCLUSIONS: High level of ERCC1 mRNA may serve as a useful prognostic factor for poor outcome in advanced NSCLC patients treated with platinum-based third-generation doublet chemotherapy and may provide important information to guide tailored therapy of NSCLC patients. |
| | |
Authors:
|
Shengxiang Ren; Songwen Zhou; Ling Zhang; Jianfang Xu; Meijun Lv; Jie Zhang; Caicun Zhou; Jie Zhang |
Related Documents
:
|
18192073 - The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis... 16135463 - Phase ii multicenter study of induction chemotherapy followed by concurrent efaproxiral... 21996263 - A phase ii evaluation of trabectedin in the treatment of advanced, persistent, or recur... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-05-26 |
Journal Detail:
|
Title: Cancer investigation Volume: 28 ISSN: 1532-4192 ISO Abbreviation: Cancer Invest. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: 2010-12-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307154 Medline TA: Cancer Invest Country: England |
Other Details:
|
Languages: eng Pagination: 1078-83 Citation Subset: IM |
Affiliation:
|
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Carboplatin / administration & dosage Carcinoma, Non-Small-Cell Lung / drug therapy, genetics*, mortality Cisplatin / administration & dosage DNA-Binding Proteins / genetics* Deoxycytidine / administration & dosage, analogs & derivatives Disease-Free Survival Drug Resistance, Neoplasm / genetics* Endonucleases / genetics* Female Humans Kaplan-Meier Estimate Lung Neoplasms / drug therapy, genetics*, mortality Male Middle Aged Neoplasm Staging Paclitaxel / administration & dosage Prognosis RNA, Messenger / analysis, biosynthesis* Reverse Transcriptase Polymerase Chain Reaction Taxoids / administration & dosage Treatment Outcome Vinblastine / administration & dosage, analogs & derivatives |
| Chemical | |
Reg. No./Substance:
|
0/DNA-Binding Proteins; 0/RNA, Messenger; 0/Taxoids; 103882-84-4/gemcitabine; 114977-28-5/docetaxel; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin; 71486-22-1/vinorelbine; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine; EC 3.1.-/ERCC1 protein, human; EC 3.1.-/Endonucleases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice...
Next Document: National Cancer Institute Cancer Center designation and 30-day mortality for hospitalized, immunocom...